Liver study for cancer drug stopped early – only 2 people joined

NCT ID NCT05209295

Terminated Knowledge-focused Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how moderate or severe liver problems change the amount of the cancer drug oral azacitidine in the blood. It was designed for adults with certain blood cancers. The study was stopped early after only 2 people enrolled, so the results are very limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACCELERATED PHASE MYELOPROLIFERATIVE NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia blast phase chronic myelogenous leukemia, BCR-ABL1 positive CD4+/CD56+ hematodermic neoplasm chronic myelomonocytic leukemia Hepatic Insufficiency leukemia, myeloid, accelerated-phase liver failure myelodysplastic syndrome myelodysplastic/myeloproliferative neoplasm myeloproliferative neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATIC INSUFFICIENCY NEOPLASMS

Contacts and locations

Locations

Local Institution

Cleveland, Ohio, 44106, United States
Local Institution - 0010

ABB, Buenos Aires F.D., C1199ABB, Argentina
Local Institution - 0011

Pilar, Buenos Aires, 1629, Argentina
Local Institution - 0012

Buenos Aires, 1426, Argentina
Local Institution - 0014

Buenos Aires, Buenos Aires F.D., C1118AAT, Argentina
Local Institution - 0015

Pamplona, Navarre, 31008, Spain
Local Institution - 0017

Barcelona, Barcelona [Barcelona], 08035, Spain
Local Institution - 0018

Badalona, Barcelona [Barcelona], 08916, Spain
Local Institution - 0069

Detroit, Michigan, 48202, United States
Local Institution - 0074

Hamburg, 20246, Germany
Local Institution - 0075

Halle, Saxony-Anhalt, 06120, Germany
Local Institution - 0076

Augsburg, Bavaria, 86156, Germany
Local Institution - 0078

Salamanca, 37007, Spain
Local Institution - 0083

Iowa City, Iowa, 52242, United States
Local Institution - 0084

Bogota, Cundinamarca, 111151, Colombia
Local Institution - 0085

Bogotá, Bogota D.C., 110131, Colombia
Local Institution - 0086

Piedecuesta, Santander Department, 681017, Colombia
Local Institution - 9003

Charlottesville, Virginia, 22903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.